Mumbai-based Larsen & Toubro's (L&T) Metallurgical, Material Handling & Water Operating Company, part of its construction division, has secured orders aggregating Rs747 crore from Coal India Ltd, Indiabulls Power Ltd and Hindalco Industries Ltd.
In material handling sector, L&T has secured a lumpsum turnkey contract worth Rs276 crore from Coal India for coal handling plant at Northern Coalfield at Amlohri, in Madhya Pradesh. To be completed in 24 months, the scope of work involves basic and detail engineering; supply and erection of mechanical, electrical and instrumentation works; complete civil and structural works, including testing and commissioning.
L&T has also won orders worth Rs260 crore from Indiabulls Power Ltd for supply and erection of coal handling plants at Amravati and Nasik thermal power plant in Maharashtra. The scope of work includes basic and detail engineering, supply and erection of mechanical, electrical and instrumentation works including testing and commissioning. The project is to be executed in 28 months.
In the metallurgical sector, L&T has secured an order valued at Rs211 crore from Hindalco Industries Ltd for aluminium rolling mill complex at Hirakud in Orissa. The scope includes civil and structural works for aluminium rolling mill and related facilities. The order has to be executed in 16 months.
On Thursday, L&T's shares ended 1.76% up at Rs1,672 on the Bombay Stock Exchange, while the benchmark Sensex closed 1.59% up at 16,922 points.
Gurgaon-based Ranbaxy Laboratories Ltd has launched a generic version of Prasugrel in India. The product called Prasita is an antiplatelet agent for prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Prasita is solely marketed by Ranbaxy in India.
Following the April 2009 launch of Olvance (olmesartan medoxomil), an antihypertensive originally discovered by Tokyo-based Daiichi Sankyo Company Ltd, Prasita is the second product from the Daiichi Sankyo portfolio to be introduced in India through the Ranbaxy business network. Ranbaxy will create awareness, understanding and acceptance of the new antiplatelet therapy among the target audiences in the country.
On Thursday, Ranbaxy's shares ended 1.34% up at Rs424 on the Bombay Stock Exchange, while the benchmark Sensex closed 1.59% up at 16,922 points.
The Chennai-based generic pharma major, Orchid Chemicals & Pharmaceuticals Ltd has entered an agreement to acquire Karalex Pharma, a US-based generic marketing and sales service company, through an all-cash deal for an undisclosed amount. The transaction is expected to close by this month subject to customary closing conditions. Through this acquisition, Orchid has created its presence in the front-end US market and will be able to reach its generic products to the US customers directly.
Headquartered in New Jersey, Karalex Pharma is a leading provider of generic pharmaceuticals focused exclusively on the US healthcare market. Orchid is a leading pharmaceutical company involved in the development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals.
On Thursday, Orchid's shares ended 4.61% up at Rs151 on the Bombay Stock Exchange, while the benchmark Sensex closed 1.59% up at 16,922 points.